Aktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors

Aktis Oncology, Inc. (AKTS) announced an update on their ongoing clinical study.

Aktis Oncology Advances First-in-Human Radiopharma Trial in Solid Tumors

The study “NECTINIUM-2” is a Phase 1b trial testing a new targeted radiation drug in patients with advanced solid tumors who have already tried other treatments. It aims to find a safe dose, check early signs of benefit, and gauge if this approach can open a new treatment path in hard-to-treat cancers.

The main treatment is [225Ac]Ac-AKY-1189, a targeted radiopharmaceutical designed to deliver radiation directly to cancer cells that express Nectin-4. A second drug, [64Cu]Cu-AKY-1189, is used for imaging to track how well the therapy reaches tumors and to help plan dosing.

This is an interventional study with one treatment group, so all enrolled patients receive the same drug without randomization. The trial is open label, meaning both doctors and patients know what is being given, and the primary goal at this stage is treatment safety and early activity rather than direct comparison to other drugs.

The trial was first submitted on May 28, 2025, marking its formal launch into the clinic. The most recent update on March 2, 2026, confirms the study remains active and recruiting, signaling ongoing data collection that will shape future development and investor expectations.

For investors, this update keeps Aktis Oncology (AKTS) in focus within the fast-growing radiopharma space led by larger players like Novartis and Eli Lilly. A clean safety profile or early tumor responses could lift sentiment and valuation, while setbacks could weigh on shares in a high-expectation, high-risk niche.

The NECTINIUM-2 study is currently ongoing and updated, with further details available on the ClinicalTrials portal.

To learn more about AKTS’s potential, visit the Aktis Oncology, Inc. drug pipeline page.